04.04.2024, Geneva - In a significant step forward for personalized cancer care, Novigenix IA, a pioneer in AI healthcare solutions, has been selected as a key partner by the IMMUcan consortium for the development of RNA sequencing biomarkers and to advance the understanding of the immune system's response to checkpoint inhibitors in cancer patients.
Geneva, January 16, 2024 - With cancer projected to escalate to 29 million cases by 2040[1], Novigenix AI, a pioneer in AI healthcare solutions, is rewriting the rules of cancer care. Their newest innovation, LITOSeek™, is primed to reshape drug development, offering a transformative leap forward. Personalized Cancer Treatment: Breaking Barriers Every cancer is
LAUSANNE, SWITZERLAND – Novigenix AI, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, recently announced the appointment of Dr Pedro Romero, MD, PhD as its Chief Medical & Scientific Officer. Dr. Romero has previously served as Director of Medical & Scientific Affairs and on the Medical Advisory Board of Novigenix
Novigenix is a pioneering, precision medicine biotech, focusing on AI-RNA analysis to improve treatment outcomes for cancer patients. Our immuno- transcriptomic solutions make earlier detection of disease possible, capture the immune profile of the patient in order to predict likely response to treatment, and enable novel drug development. The Novigenix platform is optimized for
LAUSANNE, SWITZERLAND – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced appointment of Dr. Pedro Romero as Director of Medical & Scientific Affairs. Dr. Romero has previously served on the Medical Advisory Board of Novigenix and brings over three decades of experience in immunology and immune
Expansion of Biopharma precision solutions in the field of Immuno-Oncology LAUSANNE, SWITZERLAND - November 15, 2022 – Novigenix SA, a leading data-driven precision medicine biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced successful first closing of its $20 million Series B financing round with participation from existing and new investors. Novigenix‘s
Kategorie „Innovation in der Immuno-Transkriptomik zur Früherkennung von Darmkrebs" Auszeichnung würdigt herausragende Innovation und Wirkung bei der Früherkennung von Krebs LAUSANNE, Schweiz, 22. Juli 2021 /PRNewswire/ -- Novigenix SA, ein führendes Schweizer Biotech-Unternehmen, das immuno-transkriptomische Präzisions-Onkologielösungen entwickelt und vermarktet, gab heute bekannt, dass es mit dem Felix Burda Award 2021 in der Kategorie Medizin
Mars Bleu, a campaign to raise awareness about colorectal cancer screening You may have heard about Pink October, a month dedicated to breast cancer awareness and screening. If you didn’t know it yet, there is also the national colorectal cancer awareness month; it’s March and it’s called Mars Bleu (Blue March). Colorectal cancer is